Genetic Ablation of the MET Oncogene Defines a Crucial Role of the HGF/MET Axis in Cell-Autonomous Functions Driving Tumor Dissemination.
HGF
MET
invasion
metastasis
pancreatic cancers
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 May 2023
13 May 2023
Historique:
received:
01
12
2022
revised:
03
05
2023
accepted:
08
05
2023
medline:
22
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
Cancer cell dissemination is sustained by cell-autonomous and non-cell-autonomous functions. To disentangle the role of HGF (Hepatocyte Growth Factor) and MET ligand/receptor axis in this complex process, we genetically knocked out the MET gene in cancer cells in which MET is not the oncogenic driver. In this way, we evaluated the contribution of the HGF/MET axis to cancer cell dissemination independently of its direct activities in cells of the tumor microenvironment. The lack of MET expression in MET
Identifiants
pubmed: 37345079
pii: cancers15102742
doi: 10.3390/cancers15102742
pmc: PMC10216813
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Association for Cancer Research
ID : 5 per Mille 2018 - ID 21052
Organisme : Ministero della Salute
ID : Ricerca Corrente 2022
Organisme : Associazione Italiana Ricerca sul Cancro (AIRC)
ID : IG 2021 - ID 25978 - PI: RT
Références
Br J Cancer. 2016 Feb 2;114(3):269-80
pubmed: 26766740
Cell Biochem Funct. 2013 Jun;31(4):298-304
pubmed: 22996389
Patholog Res Int. 2012;2012:960327
pubmed: 23320251
J Cell Sci. 1998 Jan;111 ( Pt 2):237-47
pubmed: 9405310
Am J Pathol. 2010 Nov;177(5):2585-96
pubmed: 20934972
Clin Cancer Res. 2005 Jun 15;11(12):4479-86
pubmed: 15958633
J Exp Clin Cancer Res. 2022 Oct 21;41(1):309
pubmed: 36271379
Int J Cancer. 2018 Oct 1;143(7):1774-1785
pubmed: 29693242
Mol Oncol. 2015 Nov;9(9):1760-72
pubmed: 26119717
Ann Surg Oncol. 2007 Sep;14(9):2600-7
pubmed: 17534684
Cancers (Basel). 2021 Jul 14;13(14):
pubmed: 34298732
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Adv Exp Med Biol. 2021;1270:31-44
pubmed: 33123991
Oncogene. 2005 Jan 6;24(1):101-6
pubmed: 15531925
Drugs. 2021 Sep;81(14):1665-1670
pubmed: 34455538
Cell. 2020 Nov 12;183(4):860-874
pubmed: 33186528
Cancer Res. 2008 Nov 15;68(22):9176-83
pubmed: 19010889
Lancet Oncol. 2008 Aug;9(8):808
pubmed: 18672217
Nat Biotechnol. 2005 Jan;23(1):108-16
pubmed: 15619618
Br J Cancer. 2020 May;122(10):1486-1495
pubmed: 32203220
Nat Rev Clin Oncol. 2020 Sep;17(9):569-587
pubmed: 32514147
Nat Rev Mol Cell Biol. 2010 Dec;11(12):834-48
pubmed: 21102609
J Clin Invest. 2002 Apr;109(7):857-62
pubmed: 11927611
Cancer Med. 2019 Sep;8(12):5574-5576
pubmed: 31397113
Mol Cancer. 2017 Dec 02;16(1):176
pubmed: 29197379
Cancer Res. 2008 Mar 1;68(5):1471-7
pubmed: 18316611
Br J Cancer. 1998 Aug;78(4):454-9
pubmed: 9716026
Ann Transl Med. 2017 Jan;5(1):5
pubmed: 28164090
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
pubmed: 18093943
J Exp Clin Cancer Res. 2021 Jan 14;40(1):32
pubmed: 33446252
Cancer Cell. 2003 Apr;3(4):347-61
pubmed: 12726861
Cancer Res. 2003 Nov 15;63(22):7926-35
pubmed: 14633723
Nat Rev Gastroenterol Hepatol. 2012 Aug;9(8):454-67
pubmed: 22710569
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6424-9
pubmed: 20332205
Cell Growth Differ. 1992 Jan;3(1):11-20
pubmed: 1534687
Clin Cancer Res. 2022 Jan 15;28(2):249-254
pubmed: 34344795
Drug Discov Today. 2021 Jan;26(1):106-121
pubmed: 33171292
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21677-82
pubmed: 21098274
Science. 2007 May 18;316(5827):1039-43
pubmed: 17463250
J Immunol. 2005 Oct 1;175(7):4745-53
pubmed: 16177122
Nat Rev Drug Discov. 2008 Jun;7(6):504-16
pubmed: 18511928
Nat Rev Cancer. 2021 Apr;21(4):217-238
pubmed: 33589810
Cancer Res. 2014 Nov 15;74(22):6598-609
pubmed: 25217525
Cell Growth Differ. 1993 Jul;4(7):563-9
pubmed: 8398896
Nat Med. 2017 Sep 8;23(9):1028-1035
pubmed: 28886003